Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 23, 2019
Athenex Completes Construction of New API Facility in Chongqing
BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
September 23, 2019
Athenex to Present at the 2019 San Antonio Breast Cancer Symposium
BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
September 23, 2019
Athenex to Present at the 2019 San Antonio Breast Cancer Symposium
BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
September 23, 2019
ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical ...
September 23, 2019
Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019
DUBLIN, Ireland, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (AVDL), a company focused on developing once-nightly sodium oxybate, FT218, for narcolepsy, today announced that ...
September 23, 2019
Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (ARCT), a leading messenger RNA medicines company focused on the discovery, ...
September 23, 2019
Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
JERUSALEM and BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX) today announced the presentation of positive results from its pharmacokinetic (PK) and pharmacodynamic ...
September 23, 2019
Lipocine Announces Presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America
SALT LAKE CITY, Sept. 23, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that four abstracts ...
September 23, 2019
Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts
NEW YORK, Sept. 23, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that a poster highlighting Iomab-B, its pivotal Phase 3 targeted ...
September 23, 2019
Immutep to Receive £4M Milestone Payment From GSK
SYDNEY, Australia, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments ...
September 23, 2019
Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY
HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
September 23, 2019
PolarityTE Announces Positive Data Showing SkinTE Regenerated Full-Thickness Skin in Difficult-to-Treat Wounds
PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced findings from a study showing positive impact of the ...
September 23, 2019
Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope
NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell ...
September 23, 2019
Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa
NEW YORK and CLEVELAND, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that ...
September 23, 2019
Tiara™ for Treatment of Mitral Regurgitation and Neovasc Reducer™ for Treatment of Refractory Angina to be Featured at TCT 2019 Conference
VANCOUVER , Sept. 23, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter ...
September 20, 2019
AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer™ Program
LAUSANNE, Switzerland, Sept. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced that it will receive the first ...
September 20, 2019
Foamix Pharmaceuticals to Present at the Cantor Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company ...
September 20, 2019
Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel ...
September 20, 2019
HTG Molecular Diagnostics Announces Pricing of $20.0 Million Aggregate Financing, Consisting of $16.6 Million Public Offering of Common Stock and $3.5 Million Concurrent Private Placement
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the pricing of an underwritten public offering ...
September 19, 2019
Sequana Medical appoints leading experts as Heart Failure Scientific Advisors
Ghent, BELGIUM – 19 September 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), innovators in the management of fluid overload in liver disease, malignant ascites ...
Page 6 of 169